For questions about this article or underlying research, email help@trefis.com.
Eli Lilly (LLY) stock trades at 46.1 times its earnings over the last twelve months, compared with 21.9 for the S&P 500. While the company is growing fast, buyers at that price are paying today for profit the business has yet to earn. So how much growth are buyers paying for at Lilly’s current price?
How Fast Must Eli Lilly Grow At This Price?
At this price, Eli Lilly would have to more than double its revenue over six years just for the share price to hold, with no return on top. That conclusion rests on three Trefis assumptions, none of which are observed in the market or stated by the company.
For the P/E Lilly settles at once its growth matures, Trefis weights the 18.0 times it uses for pharmaceuticals and biotechnology companies at 60%, and Lilly’s own average P/E at 40%. Lilly’s own average over the last twelve quarter-ends was 66.5, and the blend counts any average above 30 as 30. The result, 22.8 times, is built mostly on the industry level, not on Lilly’s own history.
At its November 12, 2026 close, Eli Lilly was worth $1,271 billion. At 22.8 times, that value implies net profit of $55.8 billion a year. Lilly’s net margin over those twelve periods averaged 25.6%, against a peak of 35.0%. Lilly would need $184 billion of revenue to earn that profit at a steady margin of 30.3%, set halfway between the two. Trefis allows six years because Lilly’s P/E today is 2.02 times the mature one and its sales are growing fast. At this price, Eli Lilly would have to grow revenue 13.4% a year from today’s $86.5 billion.
Eli Lilly’s Growth Comes Mostly From Mounjaro And Zepbound
Eli Lilly is growing far faster than that today: revenue rose 45.5% over the twelve months to September 2026. Mounjaro and Zepbound together generated more than $16 billion of revenue in fiscal Q3 2026, management said on the October 29, 2026 call. Out of the nearly $7 billion in growth the whole company reported from a year earlier, the two drugs added $6 billion. Management also said Lilly reaches only about 1 in 10 U.S. patients with these drugs, and sees years of growth ahead.
On that call, management raised its guide for fiscal 2026 revenue to a range of $91 billion to $92 billion. At the midpoint, that is 40.4% more than the $65.2 billion Lilly reported for 2025. After 2026, Lilly would still have to grow 12.9% a year through fiscal Q3 2032, well under the pace management guides for 2026. Management also raised its 2026 guide for its adjusted performance margin, but trimmed its earnings per share guide after charges for acquired research.
